Revista Brasileira de Reumatologia
Print version ISSN 0482-5004
MENDES, Reila Tainá et al. Selective inhibition of cyclooxygenase-2: risks and benefits. Rev. Bras. Reumatol. [online]. 2012, vol.52, n.5, pp. 774-782. ISSN 0482-5004. http://dx.doi.org/10.1590/S0482-50042012000500011.
The cyclooxygenase (COX) inhibitors are the most common drugs used worldwide. COX corresponds to an evolutionarily conserved class of enzymes and has two main isoforms: COX-1, which is largely associated with physiological functions, and COX-2, which is largely associated with pathological functions. Their subproducts have an important role in inflammation and pain perception. The COX-2 selective inhibition was designed to minimize gastrointestinal complications of non-selective inhibition. However, this exclusive COX-2 inhibition was associated with serious cardiovascular events, for causing an imbalance between prostacyclin and thromboxane production. The objective of this study is to discuss the mechanisms underlying the cardiovascular effects, pointing out the advantages and disadvantages of the selective or nonselective COX inhibitors.
Keywords : cyclooxygenase 2 inhibitors; cardiovascular diseases; pharmacology.